John Dobak

John Dobak, listed as chief executive, appears in our data through filings on DermTech, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 3 May 2021 to 9 March 2023, the count stands at 16 filings.

Sales make up the whole of the open-market record (12 sales, €1.4M). Outside the open market, there are 4 share grants. 2023 to date brings no purchases and 1 sale.

The record was last updated on 6 April 2023 with a share grant in DermTech, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.